DE60018761T2 - Therapeutischer antikörper gegen das muc-1-antigen und verfahren zu dessen verwendung - Google Patents

Therapeutischer antikörper gegen das muc-1-antigen und verfahren zu dessen verwendung Download PDF

Info

Publication number
DE60018761T2
DE60018761T2 DE60018761T DE60018761T DE60018761T2 DE 60018761 T2 DE60018761 T2 DE 60018761T2 DE 60018761 T DE60018761 T DE 60018761T DE 60018761 T DE60018761 T DE 60018761T DE 60018761 T2 DE60018761 T2 DE 60018761T2
Authority
DE
Germany
Prior art keywords
binding agent
tumor
antibody
muc
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60018761T
Other languages
German (de)
English (en)
Other versions
DE60018761D1 (de
Inventor
Ragupathy Madiyalakan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altarex Medical Corp
Original Assignee
Altarex Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altarex Medical Corp filed Critical Altarex Medical Corp
Application granted granted Critical
Publication of DE60018761D1 publication Critical patent/DE60018761D1/de
Publication of DE60018761T2 publication Critical patent/DE60018761T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DE60018761T 1999-08-18 2000-08-18 Therapeutischer antikörper gegen das muc-1-antigen und verfahren zu dessen verwendung Expired - Lifetime DE60018761T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14949299P 1999-08-18 1999-08-18
US149492P 1999-08-18
US16471499P 1999-11-11 1999-11-11
US164714P 1999-11-11
PCT/US2000/022890 WO2001012217A1 (en) 1999-08-18 2000-08-18 Therapeutic antibody against muc-1 antigen and methods for their use

Publications (2)

Publication Number Publication Date
DE60018761D1 DE60018761D1 (de) 2005-04-21
DE60018761T2 true DE60018761T2 (de) 2006-02-02

Family

ID=26846783

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60018761T Expired - Lifetime DE60018761T2 (de) 1999-08-18 2000-08-18 Therapeutischer antikörper gegen das muc-1-antigen und verfahren zu dessen verwendung

Country Status (7)

Country Link
EP (1) EP1204423B1 (enExample)
JP (2) JP2003519096A (enExample)
AT (1) ATE290879T1 (enExample)
AU (1) AU782569B2 (enExample)
DE (1) DE60018761T2 (enExample)
ES (1) ES2239032T3 (enExample)
WO (1) WO2001012217A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
WO2002058450A2 (en) 2000-12-22 2002-08-01 Dana-Faber Cancer Institute, Inc. Regulation of cell growth by muc1
US6627664B2 (en) * 2001-01-30 2003-09-30 Altachem Pharma Ltd. Perylenequinones for use as sonosensitizers
US20040110846A1 (en) * 2001-01-30 2004-06-10 Beatrice Leveugle Perylenequinones for use with immunotherapy agents
ES2424131T3 (es) 2001-03-27 2013-09-27 Oncothyreon Inc. Vacuna para modular respuestas inmunitarias entre T1 y T2
AU2002358246B2 (en) * 2001-10-26 2008-02-28 Oncoquest Pharmaceuticals Inc. Combination therapy for treating disease
CN100356984C (zh) * 2002-01-24 2007-12-26 巴内斯－朱威胥医院 整联蛋白靶向的影像剂
DE10256900A1 (de) 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
DE10303664A1 (de) * 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
WO2005042573A1 (en) 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
EP1848804B1 (en) * 2005-01-28 2011-10-05 Ramot at Tel Aviv University, Ltd. Anti-muc1 alpha beta antibodies
PT2366400E (pt) 2005-06-28 2016-02-02 Oncothyreon Inc Método de tratamento de doentes com uma vacina à base de glicoproteína mucinosa (muc-1)
US8506931B2 (en) 2005-08-10 2013-08-13 Quest Pharmatech Inc. Perylenequinone derivatives and uses thereof
US8454991B2 (en) 2006-07-24 2013-06-04 Quest Pharmatech Inc. Method and device for photodynamic therapy
WO2008028686A2 (en) 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
WO2008097844A2 (en) 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
WO2008097840A2 (en) 2007-02-02 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
CA2741798A1 (en) 2008-10-28 2010-05-06 Shionogi & Co., Ltd. Anti-muc1 antibody
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
WO2011135869A1 (ja) 2010-04-28 2011-11-03 塩野義製薬株式会社 新規なｍｕｃ１抗体
JP2014518841A (ja) 2011-02-24 2014-08-07 オンコシレオン インク． アジュバントを備えたｍｕｃ１ベースのグリコリポペプチドワクチン
EP2748302B1 (en) 2011-08-22 2018-08-15 Glycotope GmbH Microorganisms carrying a tumor antigen
JP2017009287A (ja) * 2013-11-11 2017-01-12 東ソー株式会社 前立腺癌と前立腺肥大症との識別方法
JP6476170B2 (ja) 2014-04-28 2019-03-06 医化学創薬株式会社 抗ｍｕｃ１抗体又はその抗原結合性断片及びその用途
US20190343953A1 (en) * 2017-01-27 2019-11-14 Glycotope Gmbh Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
EP3794042B1 (en) 2018-05-18 2024-03-27 Daiichi Sankyo Co., Ltd. Anti-muc1- exatecan antibody-drug conjugate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020841A1 (en) * 1992-04-13 1993-10-28 Dana-Farber Cancer Institute, Inc. Antibodies specific for carcinoma-associated antigens
FI950062A7 (fi) * 1992-07-06 1995-01-05 Biomira Inc Proteiinien foroaktivaatio konjugaatiotarkoituksia varten
WO1994011508A2 (en) * 1992-11-13 1994-05-26 Cancer Research Fund Of Contra Costa Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
DE19534630A1 (de) * 1995-09-18 1997-03-20 Max Delbrueck Centrum Monoklonale Antikörper gegen epitheliales Muzin (MUC1)
WO1997042973A1 (en) * 1996-05-15 1997-11-20 Altarex, Corp. Method and composition for reconforming multi-epitopic antigens to initiate an immune response
AU6017198A (en) * 1997-01-10 1998-08-25 Altarex Corp. Substituted perylenequinones for use in photodynamic therapy
EP1056472A2 (en) * 1998-02-13 2000-12-06 BASTERT, Gunter, Prof.Dr.med.Dr.h.c. Specific antibodies against mammary tumor-associated mucin, method for production and use

Also Published As

Publication number Publication date
AU6921100A (en) 2001-03-13
ATE290879T1 (de) 2005-04-15
JP2003519096A (ja) 2003-06-17
WO2001012217A1 (en) 2001-02-22
EP1204423A1 (en) 2002-05-15
AU782569B2 (en) 2005-08-11
JP2012046518A (ja) 2012-03-08
EP1204423B1 (en) 2005-03-16
WO2001012217A9 (en) 2002-06-27
ES2239032T3 (es) 2005-09-16
DE60018761D1 (de) 2005-04-21

Similar Documents

Publication Publication Date Title
US6716966B1 (en) Therapeutic binding agents against MUC-1 antigen and methods for their use
US7147850B2 (en) Therapeutic binding agents against MUC-1 antigen and methods for their use
AU782569B2 (en) Therapeutic binding agents against MUC-1 antigen and methods of their use
DE69518919T2 (de) Autoantikörper enthaltende zusammensetzung für tumorbehandlung und -vorbeugung
DE69630890T2 (de) Peptid-immitierende substanzen in der krebstherapie
JP2002515235A (ja) 坑アミロイド抗体を用いるアミロイドの除去方法
DE69034087T2 (de) Antiidiotypischer Antikörper, der ein Immunantwort gegen ein Glykosphingolipid induziert und seine Verwendung
DE69911322T2 (de) Monoklonaler antikörper der die oligosaccharide sialinsäure n-glycolierte galactose-glucose auf bösartige tumoren erkennt und zusammensetzungen die dieser enthalten
JP2001517638A (ja) 小細胞肺癌に対するフコーシルｇｍ−１−ｋｌｈ接合体ワクチン
EP1230932A2 (de) Verwendung von Antikörpern zur Vakzinierung gegen Krebs
DE69029858T2 (de) Behandlung von einer autoimmun-krankheit
EP1229936B1 (de) Verwendung von anti-idiotypischen antikörpern als impfstoffe gegen krebs
DE60109359T2 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
AT500651B9 (de) Aktiv immunisierender antikörper
AT500648B1 (de) Set zur behandlung von krebspatienten
EP1529060B1 (de) Verfahren zur herstellung eines immunstimulatorischen muzins (muc1)
DE10296942T5 (de) Therapeutische Zusammensetzung, welche die Immunitätsreaktion verändert
AT500647A1 (de) Verwendung eines impfstoffes
WO2002087611A2 (de) Mittel humanen ursprungs zur vakzination gegen gd2-positive tumore
AT413487B (de) Verwendung von antikörpern gegen ein tumor-assoziiertes antigen
CA2380936A1 (en) Therapeutic antibody against muc-1 antigen and methods for their use
JP3006943B2 (ja) 抗糖脂質糖鎖モノクローナル抗体

Legal Events

Date Code Title Description
8364 No opposition during term of opposition